Skip to main contentSkip to navigation
Sirius Investors
argenx SE

argenx SE

ARGX
NASDAQHealthcare

argenx SE (ARGX) Investment Research Dashboard

About argenx SE (ARGX) stock analysis

Get live ARGX stock price $872.23, comprehensive argenx SE stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time ARGX stock data and investment insights.

872.23
1.87%Today
Market Cap
54.24B
Volume
293.41K
52W High
953.58
52W Low
590.78

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United St...

Company Information

CEO
Karen Massey
Sector
Healthcare
Industry
Biotechnology
Employees
1863

Contact Information

Address
Laarderhoogtweg 25
Country
NL

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Growth-oriented company with premium valuation (P/E: 78.7)

Lower volatility stock (Beta: -0.02) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for argenx SE shareholders
  • Market volatility can significantly impact stock price, especially for mid-cap stocks
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for argenx SE
  • Investors should consider how argenx SE fits within their overall portfolio allocation
  • Premium valuation (P/E: 78.7) requires strong growth to justify

Market Cap

54.24B

P/E Ratio (TTM)

78.72

Beta

-0.02

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

78/100 ⭐⭐⭐⭐⭐

Overall
+0.7%
NYSE
+0.6%
NASDAQ
+0.7%
Sector1D1W1MP/EScore
Financial Services+2.2%+3.1%+4.3%19.3
98/100⭐⭐⭐⭐⭐
Healthcare+0.7%+1.3%+1.6%24.1
78/100⭐⭐⭐⭐⭐
Communication Services+1.4%-0.7%+2.9%22.2
74/100⭐⭐⭐⭐⭐
Consumer Defensive-0.2%+1.8%+0.7%29.8
64/100⭐⭐⭐⭐
Basic Materials+0.4%+1.2%-0.2%25.2
61/100⭐⭐⭐⭐
Real Estate-0.5%+0.0%-2.4%29.2
46/100⭐⭐⭐
Energy-2.1%-3.7%-4.1%19.1
39/100⭐⭐
Utilities-1.0%+0.0%-4.4%26.8
35/100⭐⭐
Industrials+0.6%+0.4%-9.9%30.1
23/100
Consumer Cyclical+0.5%-1.5%-5.8%43.0
18/100
Technology+0.6%-1.6%-7.2%40.7
15/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-28.